New J-Code as of January 1st, 2017: J7322

A Breakthrough in
Viscoelastic Technology

  • Unique Molecular Structure for Enhanced Biomechanical Properties*1,2
    • A hydrogel with greater viscosity, elasticity and joint residence time*1,2
    • Increased joint lubrication with reduced friction*1,3
    • Ability to withstand repeated mechanical stress2
  • Long lasting efficacy in a convenient 2-dose regimen1,5
    • 86% responder rate at 6 months**4
  • Excellent Safety and Tolerability in a non-crosslinked Hydrogel1
  • Non-avian1

Make HYMOVIS® your choice for high-demand
patients with pain due to OA of the knee

Fidia offers COMPREHENSIVE SUPPORT for your patients and your practice

The HYMOVIS Support Hotline*: 1-866-HYMOVIS (1-866-496-6847)

or www.HYMOVISonline.com

Available 9 AM to 8 PM ET, Monday through Friday
Dedicated reimbursement support
Three ways to enroll: phone, fax, or web
Patient-specific insurance verifications for medical and specialty pharmacy benefits
Comprehensive prior authorization support
Claims and appeal assistance
Billing and coding guidelines
Specialty pharmacy triage upon request
Simplified ordering, billing, and return processing
Report adverse events or a product quality complaint
Contact sales representative to order posters or brochures
Medical information
* The Hotline does not file claims for callers, nor can it guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or solved by the Hotline.
No minimum order quantity
Low thresholds for contract pricing
Easy online ordering

Henry Schein

Besse

McKesson

Each carton contains two blister packs, each with a single-use syringe
3.0 mL of HYMOVIS® in a 5.0-mL single-use syringe
A hyaluronan concentration of 8 mg/mL, dissolved in physiologic saline
J-Code: J7322
CPT 20610; 20611 physician administration
Available 9 AM to 8 PM ET, Monday through Friday
Hotline: 1-866-HYMOVIS (1-866-496-6847)
Dedicated reimbursement support including:
Comprehensive prior authorization support
Patient-specific insurance verifications
Billing and coding information
Claims and appeals assistance
Simple ordering process
Report adverse event or product complaints
For Customer Service, please email us at customerservice@fidiapharma.us
For product-related specific information, please contact the Medical Office at medicaloffice@fidiapharma.us
For additional information please email us at hymovis@fidiapharma.us

Fidia offers COMPREHENSIVE SUPPORT

for your patients and your practice

The HYMOVIS Support Hotline*: 1-866-HYMOVIS (1-866-496-6847)

or www.HYMOVISonline.com

Available 9 AM to 8 PM ET, Monday through Friday
Dedicated reimbursement support
Three ways to enroll: phone, fax, or web
Patient-specific insurance verifications for medical and specialty pharmacy benefits
Comprehensive prior authorization support
Claims and appeal assistance
Billing and coding guidelines
Specialty pharmacy triage upon request
Simplified ordering, billing, and return processing
Report adverse events or a product quality complaint
Contact sales representative to order posters or brochures
Medical information
* The Hotline does not file claims for callers, nor can it guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or solved by the Hotline.

Hotline: 1-866-HYMOVIS (1-866-496-6847)

FIDIA offers

Comprehensive HYMOVIS® support

for your patients and your practice

Hotline: 1-866-HYMOVIS (1-866-496-6847)

Intended for US Residents Only

*Mechanical testing may not be indicative of human clinical outcomes
** From a multi-center open label study in 49 patients treated with Hymovis®

Indications and Important Safety Information

HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information

HYMOVIS® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS® to patients with infections or skin diseases in the area of the injection site or joint.

The safety and effectiveness of the use of HYMOVIS® have not been tested in pregnant women, nursing mothers, or children. The safety and effectiveness of the use of HYMOVIS® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established. The effectiveness of repeat treatment cycles of HYMOVIS® has not been established.

Arthralgia, transient pain, or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for HYMOVIS® was equivalent to the control group. No serious adverse events or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

Strict aseptic technique should be used by licensed medical professionals trained to deliver agents into the knee joint. Joint effusion should be removed prior to injection of HYMOVIS®. Do not use disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan can precipitate in their presence.

Patients should avoid strenuous or prolonged (eg, more than one hour) physical activities within 48 hours following the IA injection.

Please see Prescribing Information.

Rx Only